4月7日 - ** 制药商Pacira BioSciencesPCRX.O的股票在延时交易中上涨15%，至26.35美元
** PCRX称已与费森尤斯卡比公司（Fresenius Kabi）就其主导药物Exparel的专利诉讼 (link)。
** Exparel 是一种可在手术后 72 小时内延长疼痛缓解时间的药物
** 费森尤斯公司可以从2030年初开始限量销售Exparel仿制药
** 该协议允许费森尤斯公司从2039年起在美国销售Exparel，不受数量限制。
** 经纪公司杰富瑞（Jefferies）认为，和解协议是 "释放复利的关键"，并预计随着诉讼悬念的消除，该公司的收入增长将 "加速"。
** 截至上次收盘，股价年累计上涨 21.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.